WELLESLEY, MA, Janus Biotherapeutics Inc., a biotech focused on autoimmune disease treatments, has raised $1.1 million of a planned $3 million equity financing, according to SEC filings. Offering raised from six investors.

Janus Biotherapeutics Inc is a project-oriented, biopharmaceutical company focused on progressing a series of small molecule leads for the treatment of autoimmune diseases. Janus is based in the Boston area and will focus its financial and managerial resources on the preclinical development of its lead programs.